DexCom Inc. (NASDAQ:DXCM) is one of the 10 Stocks Dominating With Powerful Gains. DexCom snapped a two-day loss on Friday, jumping 6.59 percent to close at $61.63 apiece, as investor sentiment was ...

In May 2026, Dexcom disclosed FDA-enforced, Class II voluntary recalls of its G7 and ONE/ONE+ iOS and watchOS apps worldwide due to a software defect that can delay or replay glucose readings and ...

DexCom (NASDAQ:DXCM) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below provides a snapshot of their recent ratings, ...

DexCom (NASDAQ:DXCM) used its 2026 Investor Day to outline a long-range plan centered on new product launches, broader insurance coverage for continuous glucose monitoring, international expansion and ...

DexCom's improved fundamentals and a 15% lower stock price present a more attractive entry. Learn why DXCM stock is a Buy.

The Non-Insured Health Benefits (NIHB) program establishes exemplary coverage for Dexcom’s real-time continuous glucose monitoring system – bringing game-changing technology to more First Nations and ...

DexCom has enormous runway for growth, not just in its home market - the U.S., but internationally as well. Manufacturing efficiencies could support their international ambitions while supporting ...

First-ever automated insulin delivery with the tubeless Omnipod Insulin Management System and personal smartphone control Initially compatible with Dexcom G6 CGM, with no fingersticks* required ...